Genmab AS (Denmark) Today

GMAB Stock  DKK 2,043  2.00  0.1%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 9

 
100  
 
Zero
Low
Genmab AS is selling at 2043.00 as of the 18th of March 2024; that is -0.1 percent decrease since the beginning of the trading day. The stock's open price was 2045.0. Genmab AS has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Genmab AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of September 2022 and ending today, the 18th of March 2024. Click here to learn more.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark. The company has 65.96 M outstanding shares. More on Genmab AS

Moving together with Genmab Stock

  0.81BAVA Bavarian NordicPairCorr

Moving against Genmab Stock

  0.5GRLA GroenlandsbankenPairCorr
  0.43ALK-B ALK-Abell ASPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Genmab Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genmab AS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genmab AS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOJan Winkel
Business ConcentrationBiotechnology, Healthcare (View all Sectors)
Genmab AS (GMAB) is traded on Copenhagen Exchange in Denmark and employs 1,560 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 185.21 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genmab AS operates under Healthcare sector and is part of Biotechnology industry. The entity has 65.96 M outstanding shares. Genmab AS has accumulated about 18.08 B in cash with 2.23 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 276.57.
Check Genmab AS Probability Of Bankruptcy
Ownership Allocation
Genmab AS secures a total of 65.96 Million outstanding shares. 30% of Genmab AS outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Genmab Ownership Details

Genmab Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Genmab AS jumping above the current price in 90 days from now is about 43.88%. The Genmab AS probability density function shows the probability of Genmab AS stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon the stock has a beta coefficient of 1.2378. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Genmab AS will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Genmab AS is significantly underperforming NYSE Composite.
  Odds Below 2043.0HorizonTargetOdds Above 2043.0
55.87%90 days
 2,043 
43.88%
Based on a normal probability distribution, the odds of Genmab AS to move above the current price in 90 days from now is about 43.88 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .

Genmab AS Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Genmab AS market risk premium is the additional return an investor will receive from holding Genmab AS long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Genmab AS. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Genmab AS's alpha and beta are two of the key measurements used to evaluate Genmab AS's performance over the market, the standard measures of volatility play an important role as well.

Genmab Stock Against Markets

Picking the right benchmark for Genmab AS stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Genmab AS stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Genmab AS is critical whether you are bullish or bearish towards Genmab AS at a given time. Please also check how Genmab AS's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Genmab AS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Genmab AS Corporate Management

Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
Birgitte StephensenSenior Vice President IPR & LegalProfile
Jonathan PeacockIndependent DirectorProfile
Birgitte MScEx OfficerProfile
Daniel BrunoDirector, Employee RepresentativeProfile
Peter KristensenDirector, Employee RepresentativeProfile

How to buy Genmab Stock?

Before investing in Genmab AS, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Genmab AS. To buy Genmab AS stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Genmab AS. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Genmab AS stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Genmab AS stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Genmab AS stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Genmab AS, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Genmab Stock please use our How to Invest in Genmab AS guide.

Already Invested in Genmab AS?

The danger of trading Genmab AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Genmab AS is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Genmab AS. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Genmab AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.